Wall Street remains in the red heading into the end of the week, with major indexes posting modest midday losses in New York, though well off the session’s earlier lows.
Sentiment was buoyed by the CEO's remarks on transitioning key customers to its next-generation lidar technology, securing new contracts and expectations for lidar shipments to at least triple this year.
Citing institutional investors, Morgan Stanley’s Mike Wilson said the current weakness stemmed from the tariff and other “rapid-fire” policy announcements
Federal Reserve Chairman Jerome Powell indicated that inflation driven by new trade tariffs might be “transitory,” evoking comparisons to the Fed's 2022 misstep when it wrongly classified inflation as a short-lived
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.
Risk sentiment shows signs of recovery by midday trading in New York, as investors anxiously await the Federal Open Market Committee (FOMC) meeting at 2:00 p.m., hoping that Federal Reserve Chair Jerome Powell will offer reassuring remarks on the strength of the economy.
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.
CEO Craig Peters said the company is focused on investing in core assets, expanding its exclusive content and leveraging its unique expertise to drive sustainable customer value.
Stocks were little moved during midday Monday trading in New York, as a mixed retail sales report failed to generate a bullish response from investors.
While Friday’s action was encouraging for a potential market turnaround, we need to see further confirmation, like the Nasdaq and S&P 500 regaining their 200-day moving averages.
Both SPY and QQQ must get back over and close above their 50-WMA to convince bulls the move Friday, while a reversal in the works, is not just a dead cat bounce.
